Biotech Synergy Acquires Multi-Epitope NSCLC Cancer Vaccine Phase 2 Positive Assets and Related Patents

SAN DIEGO--(BUSINESS WIRE)--Biotech Synergy has concluded the asset transfer of multi-epitope cancer vaccine product formerly known as EP-2101 and cancer epitopes related portfolio. Emile Loria, M.D., former President and Chief Business Officer of IDM and former President & CEO of Epimmune, is the founder of Biotech Synergy.
MORE ON THIS TOPIC